



Biosign Closes Oversubscribed Private Placement

TORONTO, ONTARIO, Friday, October 09, 2009 – Biosign Technologies Inc. (**CNSX: BIO**) (the “Company” or “Biosign”) reports that its previously announced \$1 million non-brokered private placement was oversubscribed, allocated, and is closed effective today.

Contact:

Radu Leca, President & CEO
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 234
Email: ceo@biosign.com

About Biosign Technologies Inc.

Biosign provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT[®] medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign please visit <http://www.biosign.com>.

The CNSX has neither approved nor disapproved the contents of this press release.

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES